Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.71 |
| ▸ | OGFRL1 | Q5TC84 | 6/20 | 0.71 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CFTR | P13569 | 3/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564418 | 0.89 | OPRM1 (0.77) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL3563012 | 0.88 | OPRM1 (0.67) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL3572216 | 0.87 | OPRM1 (0.66) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL1304962 | 0.86 | OPRM1 (0.80) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL682338 | 0.83 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL3430861 | 0.81 | OPRM1 (0.61) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL3568578 | 0.80 | OPRM1 (0.63) | OPRM1OGFRL1OPRL1KMT2AMEN1 | |
| SCHEMBL3560603 | 0.79 | OPRM1 (0.63) | OPRM1OGFRL1OPRL1 | |
| Citric Acid SCHEMBL4434760 | 0.78 | OPRM1 (0.56) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL10038853 | 0.77 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121689-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-07-31 | — | — | EP | claimed |
| US-20100048554-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2121689-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-11-25 | — | — | EP | claimed |
| WO-2008101659-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2008-08-28 | — | — | WO | claimed |
| EP-2121689-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-2121689-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-8404740-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404740-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404740-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100048554-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048554-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048554-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2008101659-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048554-A1 | Spirocyclic Cyclohexane Compounds | OPRL1, OPRD1, OPRK1 | OPRM1 4/4885OGFRL1 5/4885OPRL1 1/4885 |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | OPRM1 1029/4885OGFRL1 4373/4885OPRL1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.